A day after a panel of advisers to the Food and Drug Administration expressed deep concerns about the use of MDMA to help treat post-traumatic stress disorder, companies working to develop other psychedelics said their optimism had not been dimmed — and that the concerns provided a clearer blueprint for what it might take to get such a drug approved.
